The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.

Abstract

OBJECTIVE:

To illustrate the increasing importance of pharmacogenetics in drug development and clinical practice through a critical analysis of the validation and licensing of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as a treatment for non-small cell lung cancer (NSCLC).

DATA SOURCES:

Journal articles and the "grey" literature were identified through a systematic search of MEDLINE (to June 2010) and the Web sites of the major drug regulators. References identified through the reference lists of major published reviews of gefitinib and Erb receptors, including EGFR, were also reviewed.

STUDY SELECTION AND DATA EXTRACTION:

A broad appraisal of the titles and abstracts of articles on gefitinib and tyrosine kinase inhibitors in lung cancer was undertaken to identify pertinent concepts and relevant publications for further analysis. Articles deemed particularly relevant were retrieved for detailed appraisal. Dossiers on the licensing of gefitinib from the Food and Drug Administration Web site and major published reviews were retrieved. Relevant pharmacogenetic issues were identified and the clinical studies addressing these were evaluated.

DATA SYNTHESIS:

Initial promising trial data for gefitinib in NSCLC led to its conditional marketing approval. When the drug's efficacy was not confirmed in a pivotal Phase 3 trial, its prescribing was restricted. Subsequent discovery of activating mutations in the tyrosine kinase domain of EGFR led to further retrospective and prospective evaluation of the drug in patients with those mutations. The new evidence was sufficiently robust to persuade the drug regulators to license the drug as first-line treatment for patients with locally advanced or metastatic NSCLC who test positive for those mutations.

CONCLUSIONS:

Pharmacogenetic evidence has played a key role in rescuing gefitinib for front-line treatment of NSCLC. This case-example portends what will be increasingly likely scenarios in the regulation and clinical validation of targeted drug therapies.

• Authors: Alain Li-Wan-Po, Peter A Farndon, Susumu Kobayashi, Tetsuya Mitsudomi, Vanessa A Potter
• Journal: The Annals of pharmacotherapy (Ann Pharmacother) Vol. 45 Issue 2 Pg. 263-75 (Feb 2011) ISSN: 1542-6270 [Electronic] United States
• PMID: 21304034 (Publication Type: Journal Article, Review)
• Copyright: © 2011 SAGE Publications.

Chemical References

• Antineoplastic Agents
• Quinazolines
• EGFR protein, human
• ErbB Receptors
• Gefitinib

Topics

• Antineoplastic Agents (pharmacokinetics)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• Clinical Trials, Phase III as Topic
• Drug Resistance, Neoplasm
• ErbB Receptors (antagonists & inhibitors, genetics)
• Gefitinib
• Humans
• Lung Neoplasms (drug therapy, genetics)
• Mutation
• Prospective Studies
• Quinazolines (pharmacokinetics)
• Retrospective Studies
• Risk Assessment
• Technology Transfer